MOTS-C 40mg research peptide UK is the bulk-format mitochondria-derived peptide for established UK laboratory programmes and institutional research requiring extended single-batch AMPK pathway studies. ≥98% purity. Janoshik tested. Same-day UK dispatch. For research use only.
Safety Information: Not intended for human or veterinary use. Use appropriate laboratory safety procedures when handling.
MOTS-C 40mg should only be used in laboratory settings by qualified personnel.
Ensure all experimental procedures comply with local and institutional regulations.
This peptide is supplied for research and scientific study purposes only.
MOTS-C 40 mg:
Click Here To View
Research use only • UK dispatch • Orders before 4pm ship same day • Secure checkout
MOTS-C 40mg Research Peptide UK
MOTS-C 40mg is a higher-mass laboratory format of the mitochondria-derived peptide MOTS-C, a 16-amino acid peptide encoded within the mitochondrial 12S rRNA region. Identical compound to MOTS-C 10mg — a 16-amino acid peptide encoded within the mitochondrial 12S rRNA gene, primary mechanism of AMPK pathway activation via mitochondria-to-nucleus translocation under cellular stress conditions — providing four times the compound volume of the 10mg format for institutional programmes and multi-researcher laboratory settings.
The MOTS 40mg research peptide format is appropriate when the MOTS-C 10mg pilot phase has validated the experimental design and the research programme requires extended operation from a single verified batch. Single-batch supply is particularly important for longitudinal AMPK pathway studies where batch-to-batch variability would introduce systematic error across time-series data. Institutional supply contexts — where multiple researchers within the same programme access the same compound batch — are a primary application of the 40mg format. This ensures CoA consistency across all users and satisfies the procurement and documentation requirements of university and CRO laboratory settings.
High-throughput AMPK pathway assays represent another primary application of MOTS-C 40mg. When study designs involve multiple concentration gradients, multiple time points, and multiple biological replicates simultaneously — as is typical in gene expression studies examining AMPK-driven downstream targets — the 40mg format provides the compound volume to complete the full study design from a single, analytically verified batch without the risk of running out of material mid-study.
For the mechanism of action, AMPK pathway detail, and guidance on experimental design considerations specific to MOTS-C, researchers should consult the MOTS-C 10mg product page and the MOTS-C research guide on the Ascend Peptides UK blog. The fundamental science is identical between both formats; only the research scale differs.
MOTS-C 40mg has no mechanistic overlap with any other compound in the Ascend Peptides UK range. Its mitochondria-derived origin and AMPK-centred mechanism make it a uniquely positioned research tool in the UK market.
All batches were independently tested by Janoshik. HPLC greater than or equal to 98%. LC-MS confirmed. Verifiable CoA.
For laboratory handling purposes, MOTS-C may be reconstituted using sterile aqueous solutions such as bacteriostatic water, depending on experimental requirements. Store lyophilised material at -20°C.
DISCLAIMER: For in-vitro research only. Not an MHRA-licensed medicine.
A curated entry point for buyers comparing quality, documentation, and availability.
UK same-day dispatch – PCI-
compliant payments –
Laboratory research only
© 2026 by Ascend Peptides Uk.
